Aug. 6 at 12:08 PM
$ABUS Arbutus Biopharma Q2 2025 Form 10-Q Summary
Financials:
Cash:
$98.1M (down from
$122.6M); no debt.
Q2 Revenue:
$10.7M (vs.
$1.7M Q2 2024), boosted by
$9.6M Qilu deferred revenue.
Q2 Net Income:
$2.5M (
$0.01/share) vs.
$19.8M loss in Q2 2024.
H1 Net Loss:
$22.0M (
$0.12/share) vs.
$37.7M in H1 2024.
Operating Expenses:
$9.3M in Q2 (vs.
$23.3M);
$36.7M in H1 (vs.
$44.2M), including
$12.5M restructuring charge.
Cash Used:
$29.1M (H1 2025) vs.
$33.8M (H1 2024).
Operations:
Imdusiran (AB-729): RNAi for cHBV; 50% functional cure rate in low HBsAg patients (IM-PROVE I), 25% with VTP-300/nivolumab (IM-PROVE II).
AB-101: PD-L1 inhibitor in Phase 1a/1b, well-tolerated with high receptor occupancy.
Restructuring: 57% workforce cut, exited PA headquarters, stopped in-house research.
Qilu Termination: Regained global imdusiran rights in June 2025.
